Lung cancer screening by Kazerooni, Ella A.
E.A. Kazerooni (✉)
University of Michigan Medical Center,
1500 E Medical Center Drive,
Taubman Center 2910,




Abstract  Lung cancer screening
with CT remains controversial. Lung
cancer is the leading cause of cancer
death. To date, no screening test has
been demonstrated to reduce mortali-
ty. Given the large population of
adult cigarette smokers and former
smokers worldwide, there is a large
population at risk for lung cancer.
While a lot has been learned from
prospective single-arm cohort stud-
ies about the feasibility of perform-
ing annual CT to screen for lung
cancer, many questions have also
been raised. While we know that
screening for lung cancer with CT
detects many small nodules, with up
to half the subjects having a positive
baseline screen, and up to 75% of
subjects having a positive screen at
least once if screened annually for 
5 years, the great majority of these
nodules exhibit benign biologic be-
havior. The innumerable small nod-
ules detected with screening CT, and
diagnostic chest CT in general, pres-
ent a daily clinical challenge, and re-
sult in extensive medical resource
utilization and additional radiation
exposure. Algorithms for how and
when to follow small nodules detect-
ed on CT are in evolution. Ongoing
studies are designed to determine 
if lung cancer screening with CT 
reduces lung cancer mortality. 
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Introduction
There is a need for a test to screen for lung cancer. Ciga-
rette smoking is the leading cause of lung cancer, and
there is a large population of current and former smokers
worldwide. In the United States alone there are over 90
million adults who are current or former smokers, repre-
senting over 40% of the US adult population [1]. Lung
cancer is the leading cause of cancer death in the United
States for both men and women, having surpassed breast
cancer in women. Lung cancer kills more men and wom-
en in the US each year than cancers of the breast, colon,
and prostate gland combined. Whereas screening tests
are available and demonstrated to be effective in reduc-
ing mortality from these latter cancers, no screening test
has yet been proven to reduce lung cancer mortality. 
Attempts to screen for lung cancer with sputum test-
ing and/or chest radiography have not been shown to 
reduce lung cancer mortality [2]. Advances in CT scan-
ner technology over the past decade, with single-detector
CT scanners followed by multidetector CT scanners clin-
ically in use with up to 64 detectors, make consistent
high-resolution imaging of the lungs possible in only a
few seconds.
Lung cancer screening with CT is a widely controver-
sial subject. While there are many things we know about
the detection of small nodules or nodule-like abnormali-
ties on CT, and how CT performs relative to other radio-
logic tests such as the chest radiograph, many questions
remain unanswered at this time. 
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Lung cancer screening with CT: the data
Many single-arm prospective cohort studies using CT for
lung screening have been published, from Asia, Europe,
and North America, cumulatively reporting more than 
20 000 subjects to date. At baseline, referred to as preva-
lence data, these studies have found noncalcified nodules
in 12–51% of patients, with cancer detection rates in
screening trials ranging from 0.4 to 3.0% [3–7]. The per-
centage of cancers detected that are stage I is generally
high, but ranges from highs of 84–93% in Japan, to lows
of 44% in Florida, and 58% in Germany. Cancers detect-
ed on screening CT at baseline have a mean size of 
15–25 mm, with 0-56% of cancers being 1 cm or smaller
in size [3-6, 8]. 
Incidence data refers to annual screenings performed
annually after the baseline screen, in which changes
from the baseline examination are used to determine if
the new CT examination is positive. Centers that have
published incidence data report that 2.5–12% of subjects
have new or growing lung nodules, a cancer detection
rate of 0.26–1%, with 71–89% of cancers being stage I
[6, 9, 10]. Of note, in one study 20% of the nodules
found on screening examinations performed 1 year after
baseline were not originally detected by the CT readers
on the baseline screen, demonstrating how difficult the
detection of small nodules can be on large CT datasets
generated by today’s multidetector CT scanners, often
with 1–2-mm slice thickness throughout the entire lungs
[6]. Computer-assisted diagnostic (CAD) tools that can
assist the reader by identifying candidate lung nodules,
similar to mammography, are becoming available. Addi-
tional CAD tools that may be of use to readers include
estimation of nodule volume, and change in volume over
time, so that doubling time can be calculated, thereby as-
sessing biologic behavior [11]. While many tools exist,
head-to-head comparison of these tools in workstation
face-off settings has demonstrated inconsistency among
them, and further refinement of these tools is still neces-
sary. 
After 5 years of annually screening 1520 subjects at
the Mayo Clinic, 3356 total noncalcified lung nodules
were found (mean 2.2 per subject), in 1118 or 74% of
subjects [12]. Drawing on these data, three in four sub-
jects enrolled in annual screening CT programs may
have at least one noncalcified nodule over a 5-year peri-
od that warrants further evaluation. This evaluation may
include at a minimum serial CT scans, and possibly PET
scan, percutaneous biopsy, bronchoscopy, or even surgi-
cal resection, each with its attendant risks for morbidity,
and in some cases, mortality. For example, screening CT
with follow-up CT examinations for small nodules is as-
sociated with additional radiation exposure. According
to one estimate, if we assume that the entire US popula-
tion of 50–75-year-old current and former smokers un-
dergoes annual lung screening CT until age 75, with a
50% compliance rate, and using the atomic bomb sur-
vivor cohort for predicting risk, there would be a 1.8%
(95% CI 0.5–5.5%) increase in lung cancer attributed to
screening CT, or 36 000 additional lung cancers [13]. In
addition, these additional tests increase medical resource
utilization and expense, at a time when per capita costs
of medical care continue to rise. 
So, what we do know is that lung screening CT de-
tects many non calcified nodules, in up to half of screen-
ing individuals at baseline and up to three-quarters of in-
dividuals undergoing screening CT for 5 years. The ma-
jority of these nodules are benign. The fact that lung can-
cers found with screening CT are predominantly stage-I
cancers is promising. There is no randomized controlled
trial data of subjects undergoing and not undergoing CT,
to know if lung cancer screening with CT reduces lung
cancer mortality. The National Lung Screening Trial
(NLST), funded by the National Cancer Institute in the
Fig. 1a-c Classification of pulmonary nodules on CT. a Solid nodule. b Part-solid nodule. c Nonsolid nodule, also referred to as a focal
ground-glass opacity
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United States, is a randomized trial of CT versus chest
radiography for lung cancer screening. With a study pop-
ulation of 50 000 subjects, the NLST is powered to de-
tect a 20–25% reduction in lung cancer mortality as its
primary outcome. Secondary outcomes include all cause
mortality, stage distribution of lung cancer, and medical
resource utilization, as well as the quality of life and psy-
chological impact of a positive screen. Subjects in this
trial are currently undergoing their third annual screen-
ing CT, and no data are available at this time.
An everyday clinical question is how to manage small
lung nodules once they are detected. Nodules large
enough for percutaneous biopsy or PET scan are general-
ly 8-10 mm or larger in size. It is the smaller nodules,
that are not amenable to percutaneous biopsy or PET,
that present the greatest diagnostic dilemma. One way to
approach this is by classifying nodules into solid, part-
solid (solid and ground-glass) and nonsolid (ground-
glass) nodules (Fig. 1) [14]. This is important, as nonsol-
id or ground-glass nodules have a higher likelihood of
being malignant than solid nodules. For example, in the
Early Lung Cancer Action Project (ELCAP) baseline CT
screening cohort of 1,000 subjects, 233 had a positive re-
sult, with 31 cancers. Of the positive screens, in 44
(19%) subjects the largest nodule was either part-solid
(n=16) or nonsolid (n=28). While 7% of solid nodules
were malignant, the malignancy rate for nonsolid nod-
ules was 18% (5/28) and for part-solid nodules was 63%.
Given this information, nodules with a ground-glass or
nonsolid component may warrant more intense follow up
than solid nodules. Another way to classify the probabil-
ity of malignancy based on CT alone is nodule size. The
ELCAP group in a report of 2897 CT screened subjects
found no cancers in the 374 noncalcified nodules that
were less than 5 mm in size, while 5.9% of the 238 nod-
ules 5–9 mm in size were malignant, suggesting that
nodules 5 mm or smaller do not require follow up CT
within less than 12 months [15]. The NLST recommen-
dations are that nodules less than 4 mm go back to annu-
al screening, and do not warrant shorter-term follow-up
CT. So, for smaller nodules, less than 4–5 mm, follow-
up CT examinations at 12 and 24 months is reasonable.
Some would argue that such small nodules in patients
not at risk for lung cancer (nonsmokers) do not require
follow up at all. For nodules 5–10 mm in size, follow-up
CT is usually performed at 6, 12, and 24 months. It is
very difficult to visually estimate 1–2-mm changes in the
diameter of small pulmonary nodules. Given the in-
creased frequency of malignancy in nodules with a
ground glass or non-solid component, an additional fol-
low-up CT at 3 months is recommended. A short course
of antibiotics in the interval may be useful for these lat-
ter patients as well, so that small infectious foci may
more quickly resolve. 
Lastly, CT allows us to detect lung cancer through the
identification of changes in normal lung parenchyma.
The advantage of CT over chest radiography is that CT
can find more and smaller nodules. Basically, CT finds
small nodules that may or may not be cancer. There is
the inherent assumption that a small cancer is an “early”
cancer; however, as some studies have reported as many
as 42–56% of screen detected cancers are not “early”
stage-I cancers. In clinical practice, it is not uncommon
to come across a small adenocarcinoma when asked to
perform chest CT in a patient who presents with brain
metastases as a first manifestation of lung cancer. Fur-
thermore, there is some evidence that size is not every-
thing in lung cancer. Two studies have reported that there
is no significant relationship in either the stage distribu-
tion of cancer or cancer survival in patients with smaller
primary lung tumors [16,17]. So, the advantage of CT in
being able to find small nodules may not be enough. Ex-
tensive work is ongoing to find biomarkers that could be
screened for in blood or sputum samples in addition to or
instead of screening CT. 
Conclusion
In closing, prospective cohort studies confirm that lung
cancer CT screening is feasible, and results are encour-
aging, showing a stage shift to earlier-stage cancers than
in patients who present clinically. A mortality benefit has
not yet been demonstrated. Active research in this area is
extensive, and should provide answers to the many unan-
swered questions.
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